Malaria is a mosquito-borne parasitic disease that has deeply impacted the human population throughout recorded history. The disease burden of malaria has gradually declined over the last few decades due to continuing global efforts towards its eradication. In the past two years however, this trend has unfortunately stalled and reversed as healthcare resources are diverted to address the global COVID-19 pandemic. Though the GSK-developed RTS-S vaccine was recently approved by the WHO for malaria prevention, this tool will not be sufficient on its own to eradicate malaria, particularly as antimalarial drug resistance is rapidly spreading. The research described in this dissertation applies to two chemical scaffolds with excellent potential as antimalarial drugs, the aminoguanidines and the endochin-like quinolones.